TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6085363

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Acebutolol
Number of subjects: 35
Study: 30879810

Group type: EXPERIMENTAL
Intervention: Reconstituted alfalfa hay (RAH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dry alfalfa hay (AH)
Number of subjects: 20
Study: 29540305

Group type: EXPERIMENTAL
Intervention: Strength training at 70% of five repetition maximum (G70)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Strength training at 95% of five repetition maximum (G95)
Number of subjects: 22
Study: 27331824

Group type: EXPERIMENTAL
Intervention: l-leucine (LEU)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ursolic acid (UA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: cellulose placebo (PLC)
Number of subjects: 9
Study: 25238062

Group type: EXPERIMENTAL
Intervention: Green tea (GT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 23337636

Group type: EXPERIMENTAL
Intervention: Whites
Number of subjects: 1821

Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 1821
Study: 21233772

Group type: EXPERIMENTAL
Intervention: Resistance training for 18 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21432578

Group type: EXPERIMENTAL
Intervention: manualized cognitive-behavioural group psychotherapy plus open methylphenidate treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: supportive counselling
Number of subjects: 144
Study: 17458426

Group type: EXPERIMENTAL
Intervention: Topical cetirizine dinitrate (4.4 mg twice daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral cetirizine dihydrochloride (10 mg once daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14694177

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (CsA) and sirolimus (SRL); group 1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Full-dose cyclosporine (CsA) and mycophenolate mofetil; group 2
Number of subjects: 90
Study: 11215542

Group type: EXPERIMENTAL
Intervention: Social skills training with followup support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social skills training without followup support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard after-care treatment (comparison group)
Number of subjects: 0
Study: 9510041

Group type: EXPERIMENTAL
Intervention: Nimorazole
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 7483066

Group type: EXPERIMENTAL
Intervention: Staged resection (group T)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Acute resection (group R)
Number of subjects: 121
Study: 2218184

Group type: EXPERIMENTAL
Intervention: Global statistics (parametric or non-parametric)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Univariate ANOVA
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Bonferroni adjustment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Non-parametric methods
Number of subjects: 111
Study: 6153953

Group type: EXPERIMENTAL
Intervention: +cyanidanol-3
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 30739519

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 28297050

Group type: EXPERIMENTAL
Intervention: Computational model‐aided decision making
Number of subjects: 372

Group type: COMPARATOR
Intervention: Conventional healthcare
Number of subjects: 372
Study: 25407559

Group type: EXPERIMENTAL
Intervention: O(6)-benzylguanine (O(6)-BG) + BCNU 40 mg/m² + radiation therapy (RT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: BCNU 200 mg/m² + RT
Number of subjects: 183
Study: 24267123

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride 0.4 mg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg
Number of subjects: 400
Study: 21193925

Group type: EXPERIMENTAL
Intervention: National/international level surfers (NIN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Local level surfers (LOC)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NIN surfers
Number of subjects: 17
Study: 19711612

Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice (0.3%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (Control)
Number of subjects: 60
Study: 17503104

Group type: EXPERIMENTAL
Intervention: MDD-PTSD+ patients
Number of subjects: 677

Group type: COMPARATOR
Intervention: MDD patients
Number of subjects: 677
Study: 15542510

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori testing plus eradication therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Prompt endoscopy
Number of subjects: 500
Study: 11583187

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus doxorubicin (A) combination therapy
Number of subjects: 657
Study: 9779497

Group type: EXPERIMENTAL
Intervention: 5% salt water bath
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10% salt water bath
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20% salt water bath
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: tap water bath
Number of subjects: 24
Study: 7878580

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2405764

Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 307

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Suture of the cavity
Number of subjects: 307

Group type: COMPARATOR
Intervention: No suture
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Penrose drain
Number of subjects: 307
Study: 373651

Group type: EXPERIMENTAL
Intervention: prednisolone t-butyl acetate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: methyl prednisolone acetate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: triamcinolone hexacetonide
Number of subjects: 30
Study: 30866674

Group type: EXPERIMENTAL
Intervention: Bayesian results
Number of subjects: 933

Group type: COMPARATOR
Intervention: Frequentist results
Number of subjects: 933
Study: 30646209

Group type: EXPERIMENTAL
Intervention: 22-week qigong intervention (n=136)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Wait-list control group (n=135)
Number of subjects: 271
Study: 28449631

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg followed by 0.5 µg/kg/h until abdominal closure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study: 25863753

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 30 Gy to the site of residual disease
Number of subjects: 2126

Group type: EXPERIMENTAL
Intervention: Adequately performed RT
Number of subjects: 2126

Group type: EXPERIMENTAL
Intervention: Inadequate RT
Number of subjects: 2126
Study: 22790909

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 530

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 530
Study: 21084567

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 39
Study: 20024718

Group type: EXPERIMENTAL
Intervention: Self-selected treatment partners
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Community-based treatment partners
Number of subjects: 375

Group type: COMPARATOR
Intervention: No treatment partner
Number of subjects: 375
Study: 17067318

Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium (2-140 mg single dose, 8-70 mg twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium (doses > or =50 mg given twice daily and 105 mg once daily)
Number of subjects: 80
Study: 15325680

Group type: EXPERIMENTAL
Intervention: High wheat bran fiber (WBF) supplementation (13.5 g/d)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Low wheat bran fiber (WBF) supplementation (2 g/d)
Number of subjects: 237
Study: 11572281

Group type: EXPERIMENTAL
Intervention: Humidified conditions
Number of subjects: 463

Group type: COMPARATOR
Intervention: Nonhumidified conditions
Number of subjects: 463
Study: 9564804

Group type: EXPERIMENTAL
Intervention: 75 microg Fel d 1 peptides
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 750 microg Fel d 1 peptides
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (tetanus toxoid)
Number of subjects: 22
Study: 7940720

Group type: EXPERIMENTAL
Intervention: 1 HLA-DR antigen-matched blood
Number of subjects: 2

Group type: COMPARATOR
Intervention: Random blood
Number of subjects: 2
Study: 3108909

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31367901

Group type: EXPERIMENTAL
Intervention: Amiodarone-releasing hydrogel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no amiodarone-releasing hydrogel)
Number of subjects: 60
Study: 29171979

Group type: EXPERIMENTAL
Intervention: Cushion group (dynamic cushion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 26942345

Group type: EXPERIMENTAL
Intervention: Investigational group B streptococcal vaccine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 25716880

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation with MS-Line!
Number of subjects: 43

Group type: COMPARATOR
Intervention: No cognitive rehabilitation (Control)
Number of subjects: 43
Study: 23771456

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth wash with chromic catgut sutures
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Warm saline mouth wash with chromic catgut sutures
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth wash with vicryl sutures
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Warm saline mouth wash with vicryl sutures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Warm water mouth wash with vicryl sutures
Number of subjects: 100
Study: 19967581

Group type: EXPERIMENTAL
Intervention: Single-leg heel raises
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rowing ergometer exercise
Number of subjects: 20
Study: 19130855

Group type: EXPERIMENTAL
Intervention: Yoga based lifestyle intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study: 16645152

Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET (175 microg/275 microg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral E2/NETA (1 mg/0.5 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral E2/NETA
Number of subjects: 90
Study: 14652672

Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy (50.4 Gy for pN0 or 54.0 Gy for pN1/x)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Number of subjects: 36
Study: 10988126

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (84 microgram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study: 8774917

Group type: EXPERIMENTAL
Intervention: Clear surgical margins (n = 134)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Close surgical margins (n = 6)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Involved surgical margins (n = 11)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Close or involved margins (n = 14)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Margins > 5 mm
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Margins < 5 mm
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Postoperative complications (fistula rates)
Number of subjects: 159
Study: 1296490

Group type: EXPERIMENTAL
Intervention: ioversol 300
Number of subjects: 79

Group type: COMPARATOR
Intervention: iopromide 300
Number of subjects: 79
Study: 6385878

Group type: EXPERIMENTAL
Intervention: cefoxitin 2 grams every 6 hours
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: cefamandole 2 grams every 4 hours
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: ticarcillin 3 grams every 4 hours and tobramycin 1.5 mg/kg every 8 hours
Number of subjects: 152
Study: 31153849

Group type: EXPERIMENTAL
Intervention: Predominant hypoautofluorescence precursor lesions
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Minimal change autofluorescence precursor lesions
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Geographic atrophy evolving from minimal change autofluorescence precursor lesions
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Incident GA
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: GA arising from predominantly normal autofluorescence
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Faster GA enlargement rates
Number of subjects: 109
Study: 30116124

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 12

Group type: COMPARATOR
Intervention: CET
Number of subjects: 12
Study: 25955866

Group type: EXPERIMENTAL
Intervention: DEX infusion at 0.5 μg/kg/h for 10 min and then adjusted to 0.2 to 0.5 μg/kg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DEX infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 60
Study: 24845086

Group type: EXPERIMENTAL
Intervention: Enhanced tipping-point displays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tipping-point analysis
Number of subjects: 0
Study: 22202972

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 7.5 g/day from the day after surgery until the 7th postoperative day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no DKT)
Number of subjects: 30
Study: 19451347

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13608
Study: 18200396

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16296572

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once daily
Number of subjects: 314

Group type: COMPARATOR
Intervention: losartan 50 mg once daily
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 314
Study: 12063454

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g before skin incision, 400 mg/h during operation, and 500 mg in pump priming)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 60
Study: 9706922

Group type: COMPARATOR
Intervention: Isoflurane (0.25%‐1%)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol (50‐200 microg x kg(‐1) x min(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Desflurane (1.4%‐6%)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane, Propofol, Desflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study: 8582464

Group type: EXPERIMENTAL
Intervention: Hamamelis distillate cream (5.35 g hamamelis distillate with 0.64 mg ketone/100 g)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.5% hydrocortisone cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: Drug-free vehicle
Number of subjects: 72
Study: 2223342

Group type: EXPERIMENTAL
Intervention: Hypobaric 0.19% bupivacaine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine
Number of subjects: 29
Study: 27205

Group type: EXPERIMENTAL
Intervention: Rimiterol (500 microgram)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Orciprenaline (1.5 mg)
Number of subjects: 10
Study: 31995130

Group type: EXPERIMENTAL
Intervention: Antidepressant medication alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressant medication in combination with cognitive behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30935866

Group type: EXPERIMENTAL
Intervention: Remifemin (cimicifuga racemose extract) combined with LHRH-a
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (standard treatment of LHRH-a)
Number of subjects: 85
Study: 29028925

Group type: EXPERIMENTAL
Intervention: Bayesian adaptation of the PK model applied at 60 min
Number of subjects: 120

Group type: COMPARATOR
Intervention: Population-based PK model (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bayesian adaptation of the PK model
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Eleveld propofol PK model
Number of subjects: 120
Study: 26041437

Group type: EXPERIMENTAL
Intervention: ScvO2 group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 23524116

Group type: EXPERIMENTAL
Intervention: Intervention groups (pre‐ or postnatal education)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Prenatal education group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 22226275

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP) infusion at 2 pmol/kg/min for 72 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP) infusion
Number of subjects: 10
Study: 19687024

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Interferon beta-1b (IFNbeta1b)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both treatments (GA and IFNbeta1b)
Number of subjects: 75
Study: 17596064

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches based on inhibition of angiogenesis
Number of subjects: 0
Study: 15579335

Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (Rispoval 4)
Number of subjects: 83
Study: 11499722

Group type: EXPERIMENTAL
Intervention: PVS-guided antiarrhythmic drug therapy (n = 142)
Number of subjects: 704

Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (controls, n = 353)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Propafenone (specific agent)
Number of subjects: 704
Study: 9592629

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 7995387

Group type: EXPERIMENTAL
Intervention: Terbutaline via p‐MDI (0.25 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler (0.25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo p‐MDI (no terbutaline)
Number of subjects: 10
Study: 2892739

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (2 X 100 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 60
Study: 30974501

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (Hb < 75 g L‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberal transfusion threshold (Hb < 95 g L‐1 in intensive care and < 85 g L‐1 outside intensive care)
Number of subjects: 0
Study: 27705888

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 7297

Group type: COMPARATOR
Intervention: nsNSAIDs
Number of subjects: 7297
Study: 26686785

Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis‐Work Instability Scale (RA‐WIS)
Number of subjects: 148
Study: 23925396

Group type: EXPERIMENTAL
Intervention: Vaginal sildenafil citrate (100 mg single dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 21282767

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 255
Study: 19309415

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO), 0.1 mg or 0.15 mg b.i.d., for 6 days
Number of subjects: 160
Study: 17372257

Group type: EXPERIMENTAL
Intervention: Reduction in fasting insulin by 1 microunit/mL
Number of subjects: 57

Group type: COMPARATOR
Intervention: Participants with >39% body fat and >4.5 microunits/mL insulin levels
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 2.0% loss of body fat over time
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Change in body fat percentage or insulin over time
Number of subjects: 57
Study: 13129740

Group type: EXPERIMENTAL
Intervention: Valsartan therapy for 8 weeks
Number of subjects: 64
Study: 12167879

Group type: EXPERIMENTAL
Intervention: Cheddar cheese
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apple juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cola beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sweetened (strawberry) yogurt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dairy products (except sweetened yogurt)
Number of subjects: 0
Study: 9185432

Group type: COMPARATOR
Intervention: PCA (Patient-Controlled Analgesia)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PCA+BI (Patient-Controlled Analgesia with nighttime morphine infusion)
Number of subjects: 36
Study: 8267401

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative chemotherapy (treatment A) [5-drug combination chemotherapy + tamoxifen]
Number of subjects: 209

Group type: COMPARATOR
Intervention: Pre- and postoperative radiotherapy (treatment B)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Responders to chemotherapy (treatment A)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Non-responders to chemotherapy (treatment A)
Number of subjects: 209